Skip to main content

Table 2 Correlation analysis between COPA expression and clinicopathological characteristics

From: Identification of COPA as a potential prognostic biomarker and pharmacological intervention target of cervical cancer by quantitative proteomics and experimental verification

Clinicopathological characteristics

Cervical AC (n = 85)

Cervical SCC (n = 55)

Score 0 n (%)

Score 1 n (%)

Score 2 +  n (%)3

P value

Score 0 n (%)

Score 1 n (%)

Score 2 +  n (%)3

p value

Stage

        

 I

1 (1.2)

7 (8.2)

50 (58.8)

0.455

2 (3.6)

18 (32.7)

27 (49.1)

0.536

 II

0 (0)

0 (0)

20 (23.5)

0 (0)

1 (1.8)

5 (9.1)

 III

0 (0)

0 (0)

7 (8.2)

0 (0)

0 (0)

2 (3.6)

PI

        

 Yes

0 (0)

0 (0)

2 (2.4)

1

0 (0)

1 (1.8)

1 (1.8)

1

 No

1 (1.2)

7 (8.2)

75 (88.2)

2 (3.6)

18 (32.7)

33 (60.0)

LNM

        

 Yes

0 (0)

1 (1.2)

10 (11.8)

1

1 (1.8)

2 (3.6)

6 (10.9)

0.331

 No

1 (1.2)

6 (7.1)

67 (78.8)

1 (1.8)

17 (30.9)

28 (50.9)

TS

        

 ≥ 2 cm

1 (1.2)

1 (1.2)

46 (54.1)

0.040

2 (3.6)

14 (25.5)

24 (43.6)

1

 < 2 cm

0 (0)

6 (7.1)

31 (36.5)

0 (0)

5 (9.1)

10 (18.1)

DSI

        

 Yes

0 (0)

3 (3.5)

43 (50.6)

0.558

2 (3.6)

14 (25.5)

23 (41.8)

0.880

 No

1 (1.2)

4 (4.7)

34 (40.0)

0 (0)

5 (9.1)

11 (20.0)

LVSI

        

 Yes

0 (0)

1 (1.2)

14 (16.5)

1

1 (1.8)

6 (10.9)

16 (29.1)

0.551

 No

1 (1.2)

6 (7.1)

63 (74.1)

1 (1.8)

13 (23.6)

18 (32.7)

  1. Stage, FIGO staging of carcinoma of the cervix uteri (2018); TS, Tumour size; DSI, Deep stromal invasion; LVSI, Lymphatic vascular space involvement; LNM, Lymph node metastasis. p < 0.05 is marked with asterisk